GET DAILY SIGNALSHeron Therapeutics (HRTX) Holds Near $0.30 as Patent Risks and Acute-Care Growth Shape the Outlook
Key Takeaways
- HRTX trades near $0.30, roughly flat over the last 30 days, after a volatile stretch that saw shares rally toward $0.42 in early October before retracing to current levels.
- Heron Therapeutics is a commercial-stage biotechnology company marketing four products: ZYNRELEF, APONVIE, CINVANTI, and SUSTOL.
- Acute-care products ZYNRELEF and APONVIE grew 35% and 74% year over year in the second quarter of 2026, while CINVANTI declined roughly 10% amid branded competition.
- Management withdrew its full-year 2026 guidance, citing uncertainty from ongoing CINVANTI patent litigation and the potential for generic entry into its largest revenue product.
- Cash, cash equivalents, and short-term investments totaled approximately $42.7 million as of June 30, 2026, with the company evaluating strategic alternatives.
- Explore additional data on Price Targets, Earnings, and Forecast to support your own research.
- Discover automated trading ideas through Trending AI Robots.
Recent Price Action and Market Snapshot
Heron Therapeutics shares have spent 2026 in a pronounced downtrend, trading firmly below the $1 level and down sharply on a year-to-date basis. Over the most recent 30-day window, however, the stock has been relatively flat, moving from a close near $0.29 in late September to roughly $0.30, a gain of about 3%. That headline stability masks meaningful intraday volatility: shares climbed above $0.42 in the first half of October before surrendering the advance and settling back toward $0.30 as investors weighed litigation risk and the company's balance-sheet position. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to peers.
As a micro-cap commercial biotech, HRTX tends to react to company-specific catalysts rather than broad sector rotations. The pullback in the second half of October coincided with investor focus on the CINVANTI patent dispute and the approaching third-quarter earnings report, scheduled for November 9, 2026.
Heron Therapeutics (HRTX) Business Overview and Competitive Position
Heron Therapeutics is a commercial-stage biotechnology company focused on acute care and oncology. Its portfolio includes four marketed products: ZYNRELEF, an extended-release local anesthetic combining bupivacaine and meloxicam for postoperative pain; APONVIE, an intravenous formulation of aprepitant for postoperative nausea and vomiting; CINVANTI, an intravenous aprepitant for chemotherapy-induced nausea and vomiting; and SUSTOL, an extended-release granisetron product that the company is winding down.
The company's growth narrative centers on its acute-care franchise. ZYNRELEF and APONVIE have driven the top line through account expansion, payer approvals, and favorable reimbursement codes, while CINVANTI remains the largest single revenue contributor. Investors follow HRTX for the balance between fast-growing acute-care products and the mature oncology segment, where branded and potential generic competition pressures CINVANTI.
Recent Developments Driving HRTX
Second-quarter 2026 results, reported in August, framed the recent trading environment. Net revenue reached $37.7 million, up slightly from $37.2 million a year earlier. ZYNRELEF generated $11.1 million in net sales, up 35% year over year, while APONVIE contributed about $4.2 million, up 74%. CINVANTI posted $21.8 million, down roughly 10%, and SUSTOL contributed about $0.5 million as its planned wind-down continued.
The most consequential development was the withdrawal of full-year 2026 guidance, which had called for net product sales of $173 million to $183 million and adjusted EBITDA of $10 million to $20 million. Management attributed the withdrawal to uncertainty surrounding ongoing CINVANTI patent litigation, noting it could not reliably forecast sales if generic competition entered the market. The company also reported net loss of $5.5 million, or $0.03 per share, for the quarter, and said it was evaluating strategic alternatives.
2026 Outlook and What Investors Should Watch
The primary catalyst ahead is the third-quarter 2026 earnings report and conference call on November 9, which should provide updated revenue trends for ZYNRELEF and APONVIE and clarify the trajectory of CINVANTI. Investors will also watch for any resolution or update on the CINVANTI patent litigation, given its direct bearing on the company's largest revenue stream and on whether prior guidance can be restored.
Beyond litigation, the durability of acute-care growth, gross-margin normalization, cash burn, and any progress on strategic alternatives will shape sentiment. The company's $42.7 million cash and short-term investment balance as of mid-2026 underscores the importance of disciplined execution. As always with micro-cap biotech, these factors carry meaningful risk, and outcomes remain uncertain.
Exploring AI Tools for Market Insights
In my analysis of names like HRTX, I often turn to Tickeron’s AI Trading Bots for a systematic view of potential signals across thousands of tickers. These tools help filter strategies by risk tolerance and timeframe, offering a data-driven complement to traditional research without replacing personal judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HRTX's RSI Oscillator ascends from oversold territory
The RSI Indicator for HRTX moved out of oversold territory on September 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In 40 of the 45 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for HRTX crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +16.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 185 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
HRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 141 cases where HRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRTX as a result. In 67 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for HRTX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 35 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
HRTX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. HRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.745) is normal, around the industry mean (2.974). P/E Ratio (-1.583) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of polymer technologies
Industry Biotechnology
Advertisement